Atezolizumab results show benefit for selected NSCLC patients

Reuters Health - 30/09/2020 - In a small group of selected patients with metastatic non-small-cell lung cancer, first-line treatment with atezolizumab extends median overall survival by just over 7 months, or 41%, compared to platinum-based chemotherapy, according to interim results of the IMpower110 study funded by Roche and Genentech. The findings, published in The New England Journal of Medicine, only apply to patients with metastatic NSCLC who had wild-type epidermal growth factor receptors (EGFR) or anaplastic lymphoma kinase (ALK) mutations and had the highest expression of programmed death ligand 1 (PD-L1). Of the more than 1.5 million people diagnosed with lung cancer each year, probably 20% to 30% of them could be candidates for the treatment under the terms of the study, lead author Dr. Roy Herbst, chief of medical oncology at the Yale University Cancer Center, told Reuters Health in a telephone interview. Out of the 572 volunteers enrolled in IMpow...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 September, 202021 October, 2020